2587 (2587) Fair Value & Analysis

Healthcare · Market cap HK$2.1B

2 2587 2587 · HK

PriceHK$2.38

Fair ValueHK$1.47

Upside-38.2%

Quality45/100

Watch 2587 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$1.10 – HK$1.84

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price −32.0% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$2.23 – HK$21.85 · fair‑value band HK$1.10 – HK$1.84 · the HK$2.38 price screens above the HK$1.47 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2587 (2587) currently trades at HK$2.38, while our model-based Fair Value estimate is HK$1.47 — implying the stock looks roughly 38.2% overvalued today. We read business quality at 45/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 2587 generated revenue of HK$1.6B at a net margin of 3.6%. Revenue grew 77.3% year over year. It earns a return on equity of 21.1%. The stock trades on a trailing P/E of 34.0. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.6B

Revenue growth (YoY) +77.3%

Net margin 3.6%

Return on equity 21.1%

Free cash flow HK$40.2M FY2025

P/E ratio 34.0

More key figures

Operating margin 4.5%

EPS (TTM) HK$0.0100

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2587 reported revenue of HK$1.6B in FY2025 versus HK$431M in FY2021, a compound +38.0%/yr. Reported net income was HK$55.7M in FY2025.

Revenue +38.0%/yr

FY21 HK$431M

FY22 HK$569M

FY23 HK$1.2B

FY24 HK$1.2B

FY25 HK$1.6B

Net income

FY21 −HK$157M

FY22 −HK$258M

FY23 −HK$310M

FY24 −HK$268M

FY25 HK$55.7M

Is 2587 fairly valued? → Check now

Similar stocks

6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Veeva Systems Inc VEEV	$163.76	$103.58	-37%
Pro Medicus Limited PME	A$172.80	A$32.25	-81%
BrightSpring Health Services, Inc BTSG	$57.40	$23.87	-58%
Tempus AI, Inc TEM	$48.61	$12.67	-74%
HealthEquity, Inc HQY	$89.72	$54.47	-39%
M3, Inc MTHRY	$5.03	$7.44	+48%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2587 (2587) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$1.47 versus a price of HK$2.38 — about −38% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 2587?

Our model-based fair value for 2587 is HK$1.47 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$2.38.

What is the quality score of 2587?

2587 has a Quality Score of 45/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2587 (2587)?

2587 reported trailing-twelve-month revenue of about HK$1.6B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2587?

The net profit margin of 2587 is about 3.6%, meaning it keeps roughly 3.6% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.